2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Harmful

Warning

H319Causes serious eye irritation

Identifiers

IUPAC Name

(6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate

InChIKey

WKJGTOYAEQDNIA-IOOZKYRYSA-N

SMILES

C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl.O

Synonyms (26)

Cefaclor (USP)
70356-03-5 (hydrate)
Alfatil
Alfatil Kapseln
CEFACLOR [MART.]
Ceclor (TN)
Cefachlor
Cefaclor monohydrate
Di staclor
Keflor
Kefolor
Kefolor Suspension
Lilly 99638 hydrate
Muco Panoral
Panacef
Panoral

Sourcing Cefaclor monohydrate?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request Supplier? List your product for this CAS

Cefaclor monohydrate

Related Compounds

Related Reading

Safety Reference